CHIEF DIRECTOR’S MESSAGE

We engage in the development of next-generation medical technology through research focusing on human adipose-derived mesenchymal stem cell – derived endogenous biological microparticles (EBMs) .

From stem cells to endogenous biological particles
Stem cells have long been the focus of attention in the field of regenerative medicine from the perspective of stem cell transplantation. In recent years, however, attention has been focused not on the cells themselves, but on the endogenous biological particles of the cells, and research reports have emerged. Specifically, growth factors secreted by individual stem cells and components contained in extracellular vesicles are thought to have an effect on the organism. However, since these components are thought to act individually and in complex ways, they are currently incompatible with the medical licensing system of Western medicine, which is based on the assumption that a single component is used to target the affected area. On the other hand, there is a similarity with Oriental medicine, which focuses on normalizing the homeostasis of the whole body. For example, Chinese herbal medicine is a combination of several herbal medicines that produce different effects depending on the ratio of the herbs. The same can be assumed for the components of endogenous biofine particles. In other words, the endogenous bio-particles may contribute to normalization by treating patients who have lost their homeostasis. It is hypothesized that stem cell function is regulated by factors contained in endogenous bio-particles. Recent research is now turning to endogenous bio-microparticles. In this context, we at Advalife Science have been accumulating knowledge on our own protocols through research on endogenous bio-particulate preparations.

We look forward to making an advanced contribution to the field of endogenous bio-particles, which has been the focus of much attention in recent years.
We look forward to contributing to the development of our business field through the supply of endogenous bio-particles and collaboration with you.
I would like to conclude my greetings by wishing you all good health.

To realize a society where everyone is able to enjoy an affluent life

We believe that placing our efforts into discovering and developing new approaches is the best way to support growth and evolution as we strive to provide better solutions for customers. The goal of Advalife Science is to continue providing valuable solutions in a timely manner to deepen the trusting relationships we have built with our customers.

Sumitake Abe, Chief Director

[Profile] Sumitake Abe
February 1991: Join Pharmacia (present-day Pfizer Inc.)
May 2001: Director, Iberica International Corporation (present-day Iberica Holdings)
April 2003: President, Iberica Holdings
April 2008: Part-time lecturer, Faculty of Medical Sciences, Graduate School of Medical Sciences, Kyushu University
July 2011: President, IBERICA Co., Ltd.
May 2020: President, MedBis Co., Ltd.
October 2021: Chief Director, General Incorporated Association Advalife Science